The Filing Desk

Ardent Health

ARDT · NYSE · Health Care · Financials, fiscal 2022 to 2025

ARDT · Last close · November 19, 2026
$14.50
Value Ardent Health yourself

Ardent Health's revenue rose 6.0% to $6.3 billion in fiscal 2025. Its net margin was 2.1%, down from 3.5% a year earlier. The diluted share count rose 6.6%.

Ardent Health, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001628280-26-018174 Updated
Revenue
$6.3B
6.0%
Net margin
2.1%
1.4 pts
Net income
$136M
35.4%
Free cash flow
—
 
Return on equity
11.2%
12.1 pts
Market cap
$2.1B
Nov 19 close
P/E
14.1x
On $1.03 EPS, 4 qtrs

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ardent Health does

Ardent Health is a holding company whose affiliates run acute care hospitals and other health care facilities and employ physicians. It operates in eight mid-sized urban markets across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho and Kansas.

It provides general and specialty services, such as internal medicine, surgery, cardiology, oncology, orthopedics, women's services, neurology, urology and emergency care, both in hospitals and in outpatient settings. It also runs clinics and telehealth services. It reports one segment, health care services, and earns its revenue from patient care, paid largely by government programs like Medicare and Medicaid and by commercial insurers.

Ardent often works through joint ventures with academic medical centers, not-for-profit hospital systems and community physicians. It describes this joint venture model as a key part of how it operates. It became a public company through an initial public offering in July 2024.

Its biggest risks, as it describes them

  • Changes in Medicare, Medicaid and other government health care programs could cut its revenue.
  • Competition in its markets could reduce patient volumes.
  • Trouble recruiting and keeping physicians, nurses and other staff, and the cost of labor.
  • Its growth depends on completing acquisitions and joint ventures on acceptable terms.
From Ardent Health's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2022 to 2025, earnings per share fell 13.8% a year and net income 10.4% a year, as new shares raised the share count by 12% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25
Cash and short-term investments456438557710
Debt incl. finance leases—1,2091,1351,140
Net debt (negative means net cash)—771578431
Net debt to EBITDA————
Debt to equity—1.8x1.0x0.9x
Interest coverage————
Current ratio—1.6x1.9x2.0x
Quick ratio—1.5x1.8x1.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Ardent Health's filings doesn't give both for any year, so free cash flow is left out.

Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ardent Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Ardent Health says to expect

  • Full year 2026: adjusted EBITDA and revenueThe Company is increasing its full-year 2026 adjusted EBITDA financial guidance to $500 – 535 million from $485 – 535 million . The Company is maintaining its full-year 2026 revenue outlook of $6,400 – 6,700 million .
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $186,400 of Ardent Health shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jun 5, 2026Robert DeMichieiDirectorBought11,260$8.73$98,300Form 4
Jun 5, 2026Alfred LumsdaineChief Financial OfficerBought10,000$8.81$88,100Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score——6 of 8
Rule of 40———
Altman Z''———
Accruals ratio—−2.2%−6.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positive—PassPass
Cash from operations is positivePassPassPass
Return on assets rose——Fail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets——Pass
Current ratio rose—PassPass
Share count didn't risePassFailFail
Gross margin rose———
Revenue rose relative to assets——Pass
F-score——6 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Ardent Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Ardent HealthFY256.0%————6
Encompass HealthFY2510.5%—7.4%15.8%1.7x8Compare
Option Care HealthFY2513.0%6.0%3.8%11.4%2.3x5Compare
PACS GroupFY2529.3%5.8%5.7%17.5%—6Compare
Ensign GroupFY2518.7%8.4%—19.7%−0.8x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

4 years of figures

Fiscal yearFY22FY23FY24FY25
Income statement
Revenue5,1305,4105,9666,324
Revenue growth—5.5%10.3%6.0%
Gross profit————
Research and development————
Operating income————
Net income18954210136
Diluted EPS (US$)1.500.431.580.96
Diluted shares (millions)126126133142
Cash flow
Cash from operations−38222315470
Capital expenditure————
Free cash flow————
Dividends paid175000
Share buybacks0000
Acquisitions00362
Stock-based compensation————
Balance sheet at fiscal year end
Cash and short-term investments456438557710
Debt incl. finance leases—1,2091,1351,140
Total assets—4,7324,9565,290
Total liabilities—3,6493,4343,605
Shareholders' equity1,0406711,1311,288
Margins and ratios
Gross margin————
Operating margin————
Net margin3.7%1.0%3.5%2.1%
Free cash flow margin————
Rule of 40 (growth + FCF margin)————
Return on capital————
Return on equity——23.3%11.2%
Return on assets——4.3%2.6%
Net debt to EBITDA————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ardent Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ardent Health.